SWAV vs. PODD, SOLV, TFX, PEN, INSP, GMED, BAX, GKOS, HAE, and MMSI
Should you be buying Shockwave Medical stock or one of its competitors? The main competitors of Shockwave Medical include Insulet (PODD), Solventum (SOLV), Teleflex (TFX), Penumbra (PEN), Inspire Medical Systems (INSP), Globus Medical (GMED), Baxter International (BAX), Glaukos (GKOS), Haemonetics (HAE), and Merit Medical Systems (MMSI). These companies are all part of the "surgical & medical instruments" industry.
Insulet (NASDAQ:PODD) and Shockwave Medical (NASDAQ:SWAV) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, community ranking, dividends and earnings.
Shockwave Medical has a net margin of 20.17% compared to Shockwave Medical's net margin of 12.16%. Shockwave Medical's return on equity of 32.19% beat Insulet's return on equity.
95.4% of Shockwave Medical shares are held by institutional investors. 0.5% of Insulet shares are held by company insiders. Comparatively, 3.4% of Shockwave Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Insulet presently has a consensus price target of $240.33, suggesting a potential upside of 36.89%. Shockwave Medical has a consensus price target of $309.11, suggesting a potential downside of 6.51%. Given Shockwave Medical's stronger consensus rating and higher possible upside, analysts plainly believe Insulet is more favorable than Shockwave Medical.
Insulet received 575 more outperform votes than Shockwave Medical when rated by MarketBeat users. Likewise, 66.01% of users gave Insulet an outperform vote while only 55.83% of users gave Shockwave Medical an outperform vote.
Insulet has higher revenue and earnings than Shockwave Medical. Insulet is trading at a lower price-to-earnings ratio than Shockwave Medical, indicating that it is currently the more affordable of the two stocks.
In the previous week, Insulet had 5 more articles in the media than Shockwave Medical. MarketBeat recorded 12 mentions for Insulet and 7 mentions for Shockwave Medical. Shockwave Medical's average media sentiment score of 0.87 beat Insulet's score of 0.86 indicating that Insulet is being referred to more favorably in the media.
Insulet has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.Comparatively, Shockwave Medical has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500.
Summary
Insulet beats Shockwave Medical on 11 of the 18 factors compared between the two stocks.
Get Shockwave Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for SWAV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SWAV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Shockwave Medical Competitors List
Related Companies and Tools
